Diabetic Foot Ulcers (DFU)

The Problem

Diabetic foot ulcers are one of the most frequent and severe complications in diabetes, often leading to chronic infection, osteomyelitis, and even amputation.

Systemic antibiotics frequently fail to reach infected tissues due to poor local blood flow, while standard care (dressings, debridement) is often insufficient.

Advanced infections may extend into bone and require partial amputation, significantly reducing patients’ quality of life. 

Prolonged antibiotic therapy adds systemic toxicity and contributes to antimicrobial resistance.

The GentaGel™ Solution

  • Localized, Targeted Therapy – Delivers antibiotics directly to the infection site for effective bacterial eradication.
  • Accelerated Healing – Reduces bacterial load and promotes faster wound closure.
  • Lower Risk of Complications – Minimizes necrosis, sepsis, and amputation risk while improving overall prognosis.
  • Reduced Systemic Toxicity – Avoids adverse effects associated with prolonged systemic antibiotic use.
  • Cost-Effective Care – Faster healing shortens hospital stays and reduces overall costs.

Market Impact (U.S.)

~1.6 million DFU cases in the U.S alone.
10% require hospitalization (average 8 days).
Preventing just 25% of these hospitalizations could save ~$6.5 billion per year.

Market Impact (U.S.)​

1.6M

Cases in the U.S. alone

~20%

Resulting in 320,000 amputations

~$7B

Save in the U.S. market for even 10% reduction (very conservative)